Catalyst Event
Biogen Inc (BIIB) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/4/2026, 12:00:00 AM
The U.S. FDA granted Breakthrough Therapy Designation to salanersen, an investigational therapy for spinal muscular atrophy (SMA), to expedite its development and review. This designation is estimated to have a price impact of over 10% due to the significantly accelerated path to market for a high-potential therapy.
Korean Translation
미국 FDA에서 척수성 근위축증(SMA) 치료 후보물질 살라너센(salanersen)을 혁신치료제로 지정함. 개발 및 검토 가속화에 따른 시장 출시 단축으로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Kinder Morgan Inc. (KMI) · Other
James Holland, Chief Operating Officer, is set to retire, effective September 4, 2026. Ken Grubb, currently VP and Chief Project Officer, will succeed him as COO. The transition was announced on April 22, 2026. Impact is estimated at 1% due to the planned nature of the succession scheduled.
9/4/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Q3 2026 earnings release on 2026-08-24 scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Q2 FY2027 earnings release scheduled; medium impact from financial updates expected.
8/20/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q2 2026 earnings release on August 19, 2026, with analysts forecasting an EPS of approximately $2.21-$2.25; low impact estimated as the market typically prices in consensus expectations prior to the release expected.
8/19/2026, 12:00:00 AM
CoreWeave Inc (CRWV) · Earnings Release
Q2 2026 earnings release for August 18, 2026, is of high importance as such releases often cause >10% price impact; event scheduled.
8/18/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q2 2026 earnings release and conference call on August 18, 2026. Estimated price impact ~5% as earnings releases typically drive significant volatility; scheduled.
8/18/2026, 12:00:00 AM